Shire plots an AD­HD pub­lic spin­off as CEO Orn­skov com­pletes a top-to-bot­tom over­haul

Hard on the heels of win­ning an ap­proval for its long-last­ing ver­sion of Adder­all for AD­HD, Shire says it’s now con­sid­er­ing spin­ning off its block­buster fran­chise drugs in that field in­to a new pub­lic com­pa­ny, mark­ing a fi­nal re­struc­tur­ing that will leave the Boston-based biotech fo­cused on rare dis­eases.

Shire said in its Q2 state­ment Thurs­day morn­ing that the com­pa­ny has been do­ing a strate­gic re­view of its neu­ro­sciences di­vi­sion, con­sid­er­ing its op­tions on how best to han­dle the fran­chise, and says that a pub­lic list­ing is one big op­tion. Shire’s stock $SH­PG jumped more than 3% on the news.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.